Lucid Diagnostics Inc. (LUCD) Stock

Lucid Diagnostics Inc. (LUCD) is a Healthcare stock trading at $0.96 (as of 2026-08-20), with a market capitalization of $195.15M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on patients with gastroesophageal reflux disease and related risk of esophageal precancer and cancer. It develops diagnostic tools including the EsoGuard esophageal DNA test and the EsoCheck esophageal cell collection device, serving clinical and laboratory use; it is based in New York and is a subsidiary of PAVmed Inc.

Understand Lucid Diagnostics Inc.: how it makes money

Lucid Diagnostics develops and commercializes esophageal reflux (GERD) diagnostics, selling its EsoGuard laboratory developed esophageal DNA test and using its EsoCheck esophageal cell collection device, with revenue tied to billed tests and submitted claims.

The profit model hinges on turning EsoGuard testing into successfully billed and reimbursed activity, since the key pro forma revenue measures track billed tests and submitted claims rather than device-only sales.

Business quality (Weak): In the latest provided period (2026-03-31), revenue is shown as 0.0B and both gross margin (-29.4%) and operating margin (-964.5%) are negative, suggesting limited scale and ongoing losses based on the provided data.

Bull case

  • Focused diagnostic offering for a high-risk patient group: Lucid targets patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, including highly lethal esophageal adenocarcinoma.
  • Product system includes both a lab test and a collection device: Lead products include EsoGuard (a laboratory developed esophageal DNA test) and EsoCheck (an esophageal cell collection device), which can support an end-to-end workflow.

Bear case

  • Ongoing profitability pressure: Gross margin is negative (-29.4%) and operating margin is deeply negative (-964.5%) in the latest provided period.
  • Results may be sensitive to billing and claims execution: The provided operating revenue measures emphasize billed tests and submitted claims, so real-world reimbursement timing or claim processing could affect reported pro forma revenue.
Valuation — source: SEC EDGAR (first-party)
Price$0.96
Market Cap$195.15M
Price / Book17.86
Price / Sales35.84
FCF Yield-12.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$4.71M
Net Margin-1232.7%
Revenue Growth (YoY)26.7%
EPS Growth (YoY)0.0%
FCF Growth (YoY)7.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-9.71 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($5.42M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOLishan Aklog
Employees72
CountryUS
IPO Date2021-10-14

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • AVITA Medical, Inc. (RCEL)
  • OraSure Technologies, Inc. (OSUR)
  • InfuSystem Holdings, Inc. (INFU)
  • Utah Medical Products, Inc. (UTMD)
  • Neuronetics, Inc. (STIM)
  • Pro-Dex, Inc. (PDEX)
  • IceCure Medical Ltd (ICCM)
  • KORU Medical Systems, Inc. (KRMD)
LUCD earnings history · LUCD institutional & insider holders · LUCD KPIs & operating metrics · LUCD financials · LUCD investor presentations & press releases · LUCD SEC filings · LUCD peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.